481 related articles for article (PubMed ID: 34745134)
1. FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer.
Zhong A; Chen T; Xing Y; Pan X; Shi M
Front Immunol; 2021; 12():758648. PubMed ID: 34745134
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and immunological role of alpha-L-fucosidase 2 (
Hu Y; Tang D; Zhang P
Transl Cancer Res; 2023 Feb; 12(2):257-272. PubMed ID: 36915579
[TBL] [Abstract][Full Text] [Related]
3. SHCBP1 Is a Prognostic Biomarker Related to the Tumour Immune Microenvironment in Pan-Cancer.
Huang Y; You M; Wu Q; Zhu W; Guo F; Lin W
Ann Clin Lab Sci; 2022 Nov; 52(6):904-917. PubMed ID: 36564070
[TBL] [Abstract][Full Text] [Related]
4. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
[TBL] [Abstract][Full Text] [Related]
5. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
Zhao Q; Gao S; Chen X; Zhu X
Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
[TBL] [Abstract][Full Text] [Related]
6. CCDC137 Is a Prognostic Biomarker and Correlates With Immunosuppressive Tumor Microenvironment Based on Pan-Cancer Analysis.
Guo L; Li B; Lu Z; Liang H; Yang H; Chen Y; Zhu S; Zeng M; Wei Y; Liu T; Jiang T; Xuan M; Tang H
Front Mol Biosci; 2021; 8():674863. PubMed ID: 34055889
[TBL] [Abstract][Full Text] [Related]
7. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
PeerJ; 2022; 10():e14432. PubMed ID: 36518297
[TBL] [Abstract][Full Text] [Related]
8. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
[TBL] [Abstract][Full Text] [Related]
9.
Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
[No Abstract] [Full Text] [Related]
10. Pan-Cancer Analysis Predicts FOXS1 as a Key Target in Prognosis and Tumor Immunotherapy.
Liu Y; Tu M; Wang L
Int J Gen Med; 2022; 15():2171-2185. PubMed ID: 35241932
[TBL] [Abstract][Full Text] [Related]
11. The circadian rhythm key gene
Wu G; Ren H; Hu Q; Ma H; Chen H; Zhou L; Xu K; Ding L
Front Immunol; 2023; 14():1115809. PubMed ID: 37275880
[TBL] [Abstract][Full Text] [Related]
12. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
13. P4HA1, a Prognostic Biomarker that Correlates With Immune Infiltrates in Lung Adenocarcinoma and Pan-Cancer.
Zhao Q; Liu J
Front Cell Dev Biol; 2021; 9():754580. PubMed ID: 34966739
[No Abstract] [Full Text] [Related]
14. TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.
Wang K; Feng X; Zheng L; Chai Z; Yu J; You X; Li X; Cheng X
Front Mol Biosci; 2021; 8():690500. PubMed ID: 34262942
[No Abstract] [Full Text] [Related]
15. Pan-cancer analysis of prognostic and immunological role of IL4I1 in human tumors: a bulk omics research and single cell sequencing validation.
Chen B; Liu Y; He Y; Shen C
Discov Oncol; 2024 May; 15(1):139. PubMed ID: 38691253
[TBL] [Abstract][Full Text] [Related]
16. ISYNA1: An Immunomodulatory-Related Prognostic Biomarker in Colon Adenocarcinoma and Pan-Cancer.
Jia Z; Wan X
Front Cell Dev Biol; 2022; 10():792564. PubMed ID: 35237596
[No Abstract] [Full Text] [Related]
17. Prognostic and immunological role of Ras-related protein Rap1b in pan-cancer.
Cui G; Wang C; Lin Z; Feng X; Wei M; Miao Z; Sun Z; Wei F
Bioengineered; 2021 Dec; 12(1):4828-4840. PubMed ID: 34346294
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
19. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment.
Lv J; Jiang Z; Yuan J; Zhuang M; Guan X; Liu H; Yin Y; Ma Y; Liu Z; Wang H; Wang X
Front Immunol; 2023; 14():1093716. PubMed ID: 37006239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
